Literature DB >> 32728896

Tryptophan degradation is associated with risk-taking propensity in methamphetamine users with treated HIV infection.

Jared Lee1, Ji-Young Lee1, Christina S Meade2, Michael Cohn3, Antonio Chahine1, Samantha E Dilworth3, Jessica F Magidson4, Hetta Gouse5, Dietmar Fuchs6, Adam W Carrico7.   

Abstract

Few studies have examined neuroimmune pathways that could contribute to impulsivity in people living with HIV who use substances. Eighty-four methamphetamine-using, sexual minority men with an undetectable HIV viral load were administered the Balloon Analogue Risk Task (BART), a behavioral measure of risk-taking propensity. We examined the associations between kynurenine/tryptophan ratio and phenylalanine/tyrosine ratio with BART scores using multiple linear regression. A higher kynurenine/tryptophan ratio was independently associated with greater BART scores (beta = 0.25; 95% CI = 0.05-1.23; p = 0.034). The phenylalanine/tyrosine ratio was not significantly associated with BART scores. Findings support the need for further research to elucidate the neuroimmune mechanisms linking tryptophan degradation with impulsivity to catalyze the development novel pharmacologic treatments for people living with HIV who use methamphetamine.

Entities:  

Keywords:  HIV; Impulsivity; Methamphetamine; Risk-taking propensity; Tryptophan

Year:  2020        PMID: 32728896      PMCID: PMC7541781          DOI: 10.1007/s13365-020-00841-4

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  36 in total

1.  More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC.

Authors:  Andreas Laich; Gabriele Neurauter; Bernhard Widner; Dietmar Fuchs
Journal:  Clin Chem       Date:  2002-03       Impact factor: 8.327

Review 2.  Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications.

Authors:  Rita Z Goldstein; Nora D Volkow
Journal:  Nat Rev Neurosci       Date:  2011-10-20       Impact factor: 34.870

Review 3.  Residual immune dysregulation syndrome in treated HIV infection.

Authors:  Michael M Lederman; Nicholas T Funderburg; Rafick P Sekaly; Nichole R Klatt; Peter W Hunt
Journal:  Adv Immunol       Date:  2013       Impact factor: 3.543

Review 4.  Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research.

Authors:  William W Stoops; Craig R Rush
Journal:  Expert Rev Clin Pharmacol       Date:  2014-04-09       Impact factor: 5.045

5.  Prepulse inhibition in HIV-associated neurocognitive disorders.

Authors:  Arpi Minassian; Brook L Henry; Steven Paul Woods; Florin Vaida; Igor Grant; Mark A Geyer; William Perry
Journal:  J Int Neuropsychol Soc       Date:  2013-04-03       Impact factor: 2.892

6.  Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV.

Authors:  Andrew J Levine; Virawudh Soontornniyomkij; Cristian L Achim; Eliezer Masliah; Benjamin B Gelman; Janet S Sinsheimer; Elyse J Singer; David J Moore
Journal:  J Neurovirol       Date:  2015-12-04       Impact factor: 2.643

7.  Methamphetamine Augments Concurrent Astrocyte Mitochondrial Stress, Oxidative Burden, and Antioxidant Capacity: Tipping the Balance in HIV-Associated Neurodegeneration.

Authors:  Kathleen Borgmann; Anuja Ghorpade
Journal:  Neurotox Res       Date:  2017-10-09       Impact factor: 3.911

8.  Brief Report: Recent Methamphetamine Use Is Associated With Increased Rectal Mucosal Inflammatory Cytokines, Regardless of HIV-1 Serostatus.

Authors:  Jennifer A Fulcher; Steven Shoptaw; Solomon B Makgoeng; Julie Elliott; F Javier Ibarrondo; Amy Ragsdale; Ron Brookmeyer; Peter A Anton; Pamina M Gorbach
Journal:  J Acquir Immune Defic Syndr       Date:  2018-05-01       Impact factor: 3.731

Review 9.  Controversies in HIV-associated neurocognitive disorders.

Authors:  Sam Nightingale; Alan Winston; Scott Letendre; Benedict D Michael; Justin C McArthur; Saye Khoo; Tom Solomon
Journal:  Lancet Neurol       Date:  2014-11       Impact factor: 44.182

10.  Tryptophan Metabolism and Its Relationship with Depression and Cognitive Impairment Among HIV-infected Individuals.

Authors:  Michael R Keegan; Seetharamaiah Chittiprol; Scott L Letendre; Alan Winston; Dietmar Fuchs; Adriano Boasso; Jennifer Iudicello; Ronald J Ellis
Journal:  Int J Tryptophan Res       Date:  2016-10-26
View more
  6 in total

1.  HIV-related drivers of sexual compulsivity and sexuality in sexual minority men who use methamphetamine.

Authors:  Hema R Kondur; Tae K Lee; Roger McIntosh; Hetta Gouse; Robert Paul; Christian Grov; Dietmar Fuchs; Walter Gómez; Samantha E Dilworth; Torsten B Neilands; Adam W Carrico
Journal:  J Neurovirol       Date:  2022-07-12       Impact factor: 3.739

Review 2.  Through the Looking-Glass: Psychoneuroimmunology and the Microbiome-Gut-Brain Axis in the Modern Antiretroviral Therapy Era.

Authors:  Adam W Carrico; Emily M Cherenack; Leah H Rubin; Roger McIntosh; Delaram Ghanooni; Jennifer V Chavez; Nichole R Klatt; Robert H Paul
Journal:  Psychosom Med       Date:  2022-08-28       Impact factor: 3.864

3.  Neopterin Relates to Lifetime Depression in Older Adults With HIV on Suppressive Antiretroviral Therapy.

Authors:  Rowan Saloner; Natalie Savini; Scott L Letendre; David J Moore; Jessica L Montoya
Journal:  J Acquir Immune Defic Syndr       Date:  2022-04-01       Impact factor: 3.771

4.  Tryptophan depletion predicts lower positive affect in sexual minority men living with HIV who use methamphetamine.

Authors:  Ji-Young Lee; Tiffany R Glynn; Judith T Moskowitz; Dietmar Fuchs; Torsten B Neilands; Samantha E Dilworth; Daniel J Feaster; Allan Rodriguez; Adam W Carrico
Journal:  J Neurovirol       Date:  2021-01-18       Impact factor: 3.739

5.  Relationship of the balloon analog risk task to neurocognitive impairment differs by HIV serostatus and history of major depressive disorder.

Authors:  Rowan Saloner; Erin E Morgan; Mariam A Hussain; David J Moore; Robert K Heaton; Mariana Cherner; Igor Grant; Jennifer E Iudicello
Journal:  J Neurovirol       Date:  2022-01-03       Impact factor: 3.739

6.  Escalating morphine dosing in HIV-1 Tat transgenic mice with sustained Tat exposure reveals an allostatic shift in neuroinflammatory regulation accompanied by increased neuroprotective non-endocannabinoid lipid signaling molecules and amino acids.

Authors:  Douglas J Hermes; Ian R Jacobs; Megan C Key; Alexis F League; Barkha J Yadav-Samudrala; Changqing Xu; Virginia D McLane; Sara R Nass; Wei Jiang; Rick B Meeker; Bogna M Ignatowska-Jankowska; Aron H Lichtman; Zibo Li; Zhanhong Wu; Hong Yuan; Pamela E Knapp; Kurt F Hauser; Sylvia Fitting
Journal:  J Neuroinflammation       Date:  2020-11-18       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.